NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Research and development, 2025
- $1.0B
- YoY, 2025
- +38.9%
- 5-year CAGR
- +29.9%
- 10-year CAGR
- +28.7%
Research and development
Research and development by fiscal year
| Period | R&D | YoY |
|---|---|---|
| 2025 | $1.0B | +38.9% |
| 2024 | $731M | +29.4% |
| 2023 | $565M | +21.8% |
| 2022 | $464M | +41.4% |
| 2021 | $328M | +19.3% |
| 2020 | $275M | — |
| 2018 | $161M | +31.8% |
| 2017 | $122M | +29.2% |
| 2016 | $94M | +15.7% |
| 2015 | $81M | +75.5% |
| 2014 | $46M | +18.3% |
| 2013 | $39M | +5.6% |
| 2012 | $37M | +20.1% |
| 2011 | $31M | −0.6% |
| 2010 | $31M | −7.6% |
| 2009 | $34M | — |